中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
8期
1231-1232,1234
,共3页
高迁移率族蛋白1%炎症%瑞舒伐他汀%高脂血症
高遷移率族蛋白1%炎癥%瑞舒伐他汀%高脂血癥
고천이솔족단백1%염증%서서벌타정%고지혈증
High mobility group box 1 protein%Inflammation%Rosurvastatin%Hyperlipidemia
目的：探讨瑞舒伐他汀对高脂血症患者血清HMGB1水平的影响。方法：入选72例高脂血症患者，32例对照组。两组比较血清总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C）和高敏C反应蛋白（hs-CRP）。高脂血症患者使用瑞舒伐他汀（10mg/天）前和使用3个月后，分别通过ELISA法测定血清HMGB1水平。结果：高脂血症组， TC和LDL-C水平（6.37±0.93）mmol/L和（4.98±0.74）mmol/L均显著高于对照组（4.04±0.88）mmol/L和（2.34±0.81）mmol/L （P<0.05）；hs-CRP与HMGB1水平（3.91±1.06）mg/L和（5.46±1.53）ng/ml也显著高于对照组（1.53±0.45）mg/L和（2.15±0.96）ng/ml（P<0.05）。瑞舒伐他汀治疗三个月后，高脂血症组，TC和LDL-C水平与治疗前相比显著下降，分别为TC（治疗后：（4.27±0.89）mmol/L；治疗前：（6.37±0.93）mmol/L和LDL-C治疗后：（2.25±0.92））mmol/L；治疗前：（4.98±0.74） mmol/L；HMGB1和hs- CRP水平也较治疗前显著下降，分别为HMGB1治疗后：（3.07±1.24）ng/mL；治疗前：（5.46±1.53）ng/mL和hs-CRP（治疗后：（1.87±0.79）mg/L；治疗前：（3.91±1.06）mg/L，前后比较均有P<0.05。结论：高脂血症患者血清HMGB1水平增加，而瑞舒伐他汀可降低高脂血症患者血清HMGB1水平。
目的：探討瑞舒伐他汀對高脂血癥患者血清HMGB1水平的影響。方法：入選72例高脂血癥患者，32例對照組。兩組比較血清總膽固醇（TC），甘油三酯（TG），高密度脂蛋白膽固醇（HDL-C），低密度脂蛋白膽固醇（LDL-C）和高敏C反應蛋白（hs-CRP）。高脂血癥患者使用瑞舒伐他汀（10mg/天）前和使用3箇月後，分彆通過ELISA法測定血清HMGB1水平。結果：高脂血癥組， TC和LDL-C水平（6.37±0.93）mmol/L和（4.98±0.74）mmol/L均顯著高于對照組（4.04±0.88）mmol/L和（2.34±0.81）mmol/L （P<0.05）；hs-CRP與HMGB1水平（3.91±1.06）mg/L和（5.46±1.53）ng/ml也顯著高于對照組（1.53±0.45）mg/L和（2.15±0.96）ng/ml（P<0.05）。瑞舒伐他汀治療三箇月後，高脂血癥組，TC和LDL-C水平與治療前相比顯著下降，分彆為TC（治療後：（4.27±0.89）mmol/L；治療前：（6.37±0.93）mmol/L和LDL-C治療後：（2.25±0.92））mmol/L；治療前：（4.98±0.74） mmol/L；HMGB1和hs- CRP水平也較治療前顯著下降，分彆為HMGB1治療後：（3.07±1.24）ng/mL；治療前：（5.46±1.53）ng/mL和hs-CRP（治療後：（1.87±0.79）mg/L；治療前：（3.91±1.06）mg/L，前後比較均有P<0.05。結論：高脂血癥患者血清HMGB1水平增加，而瑞舒伐他汀可降低高脂血癥患者血清HMGB1水平。
목적：탐토서서벌타정대고지혈증환자혈청HMGB1수평적영향。방법：입선72례고지혈증환자，32례대조조。량조비교혈청총담고순（TC），감유삼지（TG），고밀도지단백담고순（HDL-C），저밀도지단백담고순（LDL-C）화고민C반응단백（hs-CRP）。고지혈증환자사용서서벌타정（10mg/천）전화사용3개월후，분별통과ELISA법측정혈청HMGB1수평。결과：고지혈증조， TC화LDL-C수평（6.37±0.93）mmol/L화（4.98±0.74）mmol/L균현저고우대조조（4.04±0.88）mmol/L화（2.34±0.81）mmol/L （P<0.05）；hs-CRP여HMGB1수평（3.91±1.06）mg/L화（5.46±1.53）ng/ml야현저고우대조조（1.53±0.45）mg/L화（2.15±0.96）ng/ml（P<0.05）。서서벌타정치료삼개월후，고지혈증조，TC화LDL-C수평여치료전상비현저하강，분별위TC（치료후：（4.27±0.89）mmol/L；치료전：（6.37±0.93）mmol/L화LDL-C치료후：（2.25±0.92））mmol/L；치료전：（4.98±0.74） mmol/L；HMGB1화hs- CRP수평야교치료전현저하강，분별위HMGB1치료후：（3.07±1.24）ng/mL；치료전：（5.46±1.53）ng/mL화hs-CRP（치료후：（1.87±0.79）mg/L；치료전：（3.91±1.06）mg/L，전후비교균유P<0.05。결론：고지혈증환자혈청HMGB1수평증가，이서서벌타정가강저고지혈증환자혈청HMGB1수평。
To investigate the effect of rosurvastatin on serum HMGB1 level in patients with hyperlipidemia.Methods:In 72 patients with hyperlipidmia, serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) were compared with that in 32 control patients. In hyperlipidmia patients, serum HMGB1 level was also determined by ELISA before and after 3-month treatment of rosurvastatin (10 mg/day).Results:TC level and LDL-C level in hyperlipidemia group (6.37±0.94)mmol/L and (4.98±0.74)mmol/L were significantly higher than those in control group (4.04±0.88)mmol/L and (2.34±0.81)mmol/L, respectively (bothP<0.05). Hs-CRP level and HMGB1 level in hyperlipidemia group (3.91±1.06)mg/L and (5.46±1.53)ng/ml were also significantly higher than those in control group (1.53±0.45) mg/L and (2.15±0.96) ng/ml, respectively (bothP<0.05). After treating with rosurvastatin for three months, TC level and LDL-C level in hyperlipidemia group were significantly decreased compared to those of pretreatment, respectively TC: (4.27±0.89)mmol/L vs (6.37± 0.93)mmol/L and LDL-C: (2.25±0.92)mmol/L vs (4.98±0.74) mmol/L, bothP<0.05. HMGB1 level and hs-CRP level in hyperlipidemia group (3.07±1.24) ng/ml and (1.87±0.79) mg/L were also significantly decreased compared to that of pre-treatment (5.46±1.53) ng/ml and (3.91±1.06) mg/L, bothP<0.05.Conclusion:Serum HMGB1 level was increased in patients with hyperlipidemia which could be reduced by rosurvastatin.
